Barclays
REPL icon

Barclays’s Replimune Group REPL Stock Holding History

Barclays’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$686K Sell
89,622
-202,563
-69% -$1.55M ﹤0.01% 2990
2025
Q4 		$2.84M Sell
292,185
-163,677
-36% -$1.39M ﹤0.01% 2671
2025
Q3 		$1.91M Buy
455,862
+83,752
+23% +$535K ﹤0.01% 2927
2025
Q2 		$3.46M Buy
372,110
+217,314
+140% +$1.9M ﹤0.01% 2409
2025
Q1 		$1.51M Sell
154,796
-12,533
-7% -$155K ﹤0.01% 2847
2024
Q4 		$2.03M Buy
167,329
+8,838
+6% +$107K ﹤0.01% 2864
2024
Q3 		$1.74M Buy
158,491
+98,791
+165% +$1M ﹤0.01% 2968
2024
Q2 		$537K Sell
59,700
-48,830
-45% -$340K ﹤0.01% 3001
2024
Q1 		$887K Sell
108,530
-181,974
-63% -$1.49M ﹤0.01% 3216
2023
Q4 		$2.45M Buy
290,504
+172,092
+145% +$2M ﹤0.01% 2754
2023
Q3 		$2.03M Buy
118,412
+5,401
+5% +$106K ﹤0.01% 1890
2023
Q2 		$2.62M Buy
113,011
+21,482
+23% +$420K ﹤0.01% 1702
2023
Q1 		$1.62M Buy
91,529
+43,385
+90% +$1.03M ﹤0.01% 2347
2022
Q4 		$1.31M Sell
48,144
-1,529
-3% -$31.8K ﹤0.01% 2582
2022
Q3 		$858K Buy
49,673
+47,847
+2,620% +$912K ﹤0.01% 2345
2022
Q2 		$31K Sell
1,826
-3,425
-65% -$56.3K ﹤0.01% 4235
2022
Q1 		$89K Sell
5,251
-38,499
-88% -$726K ﹤0.01% 3839
2021
Q4 		$1.19M Sell
43,750
-3,205
-7% -$95.9K ﹤0.01% 2719
2021
Q3 		$1.39M Sell
46,955
-14,236
-23% -$462K ﹤0.01% 2581
2021
Q2 		$2.35M Sell
61,191
-22,609
-27% -$773K ﹤0.01% 2083
2021
Q1 		$2.56M Buy
83,800
+75,167
+871% +$2.81M ﹤0.01% 2073
2020
Q4 		$329K Sell
8,633
-917
-10% -$38.2K ﹤0.01% 3501
2020
Q3 		$220K Sell
9,550
-1,401
-13% -$31.9K ﹤0.01% 3788
2020
Q2 		$272K Sell
10,951
-3,167
-22% -$56K ﹤0.01% 3829
2020
Q1 		$140K Buy
14,118
+1,012
+8% +$15.1K ﹤0.01% 4546
2019
Q4 		$188K Buy
13,106
+6,856
+110% +$98.8K ﹤0.01% 5074
2019
Q3 		$87K Sell
6,250
-1,257
-17% -$15.4K ﹤0.01% 5581
2019
Q2 		$110K Buy
7,507
+193
+3% +$2.79K ﹤0.01% 5611
2019
Q1 		$111K Buy
7,314
+5,835
+395% +$72.7K ﹤0.01% 5276
2018
Q4 		$15K Sell
1,479
-1,320
-47% -$17.8K ﹤0.01% 6028
2018
Q3 		$45K Buy
+2,799
New +$49.1K ﹤0.01% 6145

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's REPL Position: Q1 2026 in Review

Barclays reduced its Replimune Group (REPL) stake by 69% in Q1 2026, selling an estimated $1.55M and leaving 89,622 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #2990.

Barclays first reported a position in REPL in Q3 2018 and has held it in 31 quarters since. The position peaked at $3.46M in Q2 2025. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

  • Barclays held 89,622 shares of Replimune Group worth $686K as of Q1 2026.
  • Barclays sold 202,563 Replimune Group shares in Q1 2026, an estimated $1.55M.
  • Replimune Group made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2990 holding.
  • Barclays first reported a position in Replimune Group in Q3 2018 and has held it in 31 quarters since.
  • Barclays's Replimune Group position peaked at $3.46M in Q2 2025.
  • 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.